Life Sciences Archive » July, 2014

Life Sciences - July, 2014

303 articles

• AbbVie Investor Says Brass Exposed Co. To Off-Label Claims
• OPINION: Lawyers Should Think In Terms Of Big Data
• Jones Day Video Sanction Shows Attys Can Go Too Far
• FDA Lab Test Oversight Will Touch Off Industry Tug-Of-War
• 6th Circ. Rules Breast Implants Are Tissue Expanders
• Deals Rumor Mill: Harvard Drug, Canaan, Alibaba
• Blackstone-Backed Drug Tech Co. Raises $823M In IPO
• 1st Circ. Grills Attys On Nexium Pay-For-Delay Class Cert.
• Swedish Drug Co. Meda Pays $3.1B For Rottapharm
• Bristol-Myers Must Face Out-Of-State Plavix Claims In Calif.
• 4 Goals, 4 Years And 1 Budget: The FDA's Ambitious Plan
• J&J Unit Recalls Hysterectomy Device Over Cancer Fears
• Jones Day Atty Sanctioned For Discovery Abuse In Abbott Row
• Bankrupt Natrol Gets Nod For Cerberus Settlement
• Pa. Medical Suppliers Can't Duck Antitrust Class Action
• Cephalon Can't Fight IP Battle In FTC Pay-For-Delay Suit
• Boehringer Sues Amneal To Block Generic Aggrenox
• China Trumpets Advancements In IP Protection Regime
• AstraZeneca Flaunts Stand-Alone Prospects With $2.1B Deal
• Pfizer Shells Out $635M To Beef Up Vaccines Biz
• Fed. Circ. And USPTO Diverge On Lead Compound Analysis
• Death Rattle For Unfinished Business Claims?
• Boston Scientific Wins First Pelvic Mesh Injury Trial
• NJ High Court Cases Could Limit Whistleblower Protection
• 2nd Circ. Upholds $2.5M False Ad Award To Merck
• And Now A Word From The Panel: Top 10 Venue Arguments
• FedEx Denies It Illegally Distributed Generic Valium, Xanax
• FDA Faults Impax Quality In Latest Blow To Rytary Approval
• Endo, Watson Seek Dismissal Of Lidoderm Pay-For-Delay Suits
• Abbott Holds Onto $84M Win Against Lloyd's In Ill.
• Merck Won't Join Inversion Craze, CEO Says
• House Agrees To Prescription Drug Enforcement Overhaul
• Pfizer Unit Can't End Skelaxin Pay-For-Delay Row In Pa.
• Lagging Pfizer Revenue Reinvigorates M&A Speculation
• Dealmakers Q&A: Morris Manning's David Calhoun
• Classic Issues Face Cutting-Edge Neurofeedback Practices
• Novartis Ducks Non-Negligence Claims In Zometa Suits
• FDA's Biggest New Policies Of 2014: Midyear Report
• Vascular Solutions Settles Ex-Sales Rep's FCA Suit
• Drug Discount Deal Won't Trigger Kickback Penalties: OIG
• Docs' Groups Ask CMS For Preview Of Sunshine Data Context
• IRS Releases Final Rules On Branded Prescription Drug Fee
• GSK, Teva Fight FTC Bid To Join Lamictal Args In 3rd Circ.
• Sens. Press FDA For Plan On Antibiotic Use In Farm Animals
• BakerHostetler Snags Ex-Foley & Lardner Trademark Pro
• Del Monte Sued By Vitamin Maker Over 'Nature Made' Mark
• CTCA Sues Avax For $5.8M Over Cancer Vaccine Promise
• Deals Rumor Mill: CVC, Fox, Danone
• Norton Rose Faces Renewed DQ Bid In Pamlab Suit
• Dealmakers Q&A: Burns & Levinson's Josef Volman
• EU Rule Sets Higher Standard For Medical Devices
• Don't Get Carried Away By The Inversion Craze
• What The Supreme Court Said About Patents This Term
• Endo Can't Stop Settlement Order In Frova Patent Row
• Justices Should Back Off Patent Eligibility, Michel Says
• DLA Piper Nabs Hogan Lovells Life Sciences M&A Pro
• Retroactive Inversion Ban May Kill Pending Deals
• Judge Rinses Claims From Mouthwash False Ad Row
• 1st Circ. Nexium Case May Ripple Beyond Pharma
• FDA Limits Multiproduct Comparisons In 510(k) Submissions
• Judge Asks If Dreier Fall Busts Browne Arbitration Clause
• Herbalife, Allergan Lead To Questions Over Ackman Strategy
• Calif. Buyers Ask 1st Circ. To Revive Lexapro Marketing Suit
• GSK Investigating Alleged Misconduct By Former Syria Ops
• Calif. Judge Won't Sever Walgreen Homeopathic Meds Row
• Ireland Defends Itself After Obama Blasts Inversion Surge
• Litigator's Perspective: 5 Tips On Arbitration Provisions
• Stryker Can't Ax Counterclaims In Customer Sabotage Row
• Biosimilars Clarity Coming As FDA Eyes Sandoz Application
• FDA Gives Equivalent Rating To Perrigo's Testosterone Gel
• Pa. Risperdal Judge Won't Change Mind On Nixing Punitives
• Walgreen Wins Dismissal In Pharmacy Buyout Suits
• 2nd Circ. Sides With FDA In Livestock Antibiotics Spat
• Janssen Hits Mylan With Generic Prezista Patent Suit
• Diet Drug Maker's Last-Ditch Suit Against FTC Dismissed
• House Reps. Press For Change After Ackman Allergan Bid
• Dechert Picks Up IP, Life Science Pro From Goodwin Procter
• 6 Years In, Why Haven't FRE 502(d) Orders Caught On?
• Gordon & Rees Nabs Weber Gallagher Product Liability Atty
• FDA Accepts First Biosimilar Application From Sandoz
• Valeant Files Another Complaint Over 'False' Allergan Info
• Prosecutions Loom Large In China's Food Regulatory Regime
• Amid M&A Uptick, Bidders Must Heed UK Code Changes
• Generic Drugs At 30: Fulfilling The Promise And Path Ahead
• 3rd Time's A Charm For Miss. AG's Plavix Remand Motion
• Rare Fed. Circ. Reversal Spurs Trial On Inequitable Conduct
• GNC Ducks Herbal Testosterone Supplement RICO Action
• Apotex Blocked From Continuing Generic Paxil Sales
• Bioplastics Sister Cos. Meredian, DaniMer Agree To Merge
• AIG Unit Can't Escape $3.75M Verdict In Ad Injury Case
• Nixon Peabody, Mintz Levin Blamed For Biotech's Downfall
• Government Seeks To Outsource Criminal Enforcement
• Trial-Ready In 180 Days: Prepare For SDNY's Rocket Docket
• Out-Of-State Accutane Users Shut Out Of Calif. Litigation
• No Deal In Stryker's Suit Over $3M Scheme, Judge Says
• Stalwart Firm Cementing Place As Megadeal Powerhouse
• GrayRobinson Forms Group To Target Medical Marijuana
• Shareholders Fight Hemispherx's Fee-Shifting In Del. Chancery
• $10M J&J Motrin Verdict Upheld By Pa. Appeals Court
• Insurer Sues 23andMe To Duck Coverage Of DNA Test Suits
• Stiefel Calls 11th Circ. Ruling On Duty To Disclose Confusing
• Activist Investor Ackman's Herbalife 'Deathblow' Backfires
• Deals Rumor Mill: WH Group, GlaxoSmithKline, Huarong
• Judge's Marriage Bars Other SDNY Judges From Hearing Suit
• Vitamin C Makers Tell 2nd Circ. To Uphold Chinese Law
• Vedder Price Snags Merck Patent Pro For NY Office
• German Insurer Can Continue To Fight $15M HIV Settlement
• The Promise And Problem Of Genomic Marketing
• Novus Wants Rival Sanctioned In Sex Enhancer Rip-Off Row
• Boston Scientific Wants Vaginal Mesh Expert Out Of MDL
• Braintree Says Suprep Case Doesn't Upend Drug Patent Law
• Deals Rumor Mill: Fox, Allergan, Elliott Management
• LA Sues Hospital For Spinal Implant Overbilling Scheme
• HHS Formalizes 340B Policy As Court Fight Continues
• Keep Norton Rose On Pamlab Unfair Comp Row, Judge Says
• Canada Blasts Lilly's $500M Patent Law Challenge
• Gilead Hits Lupin With Patent Suit Over HIV Drug Atripla
• Valeant Tells Regulators Allergan Is Misleading Investors
• Proskauer Can Point Finger At Accountant In J&J Fraud Suit
• Apotex 'Thumbing Its Nose' At Paxil Bar, Mylan Says
• FDA Warns Of Lethal Potential Of Caffeine Powder
• Steptoe Expands NY Office With Ex-Mayer Brown IP Litigator
• EPA May Threaten Reverse Distribution Of Pharmaceuticals
• FDA To Examine Teen Reactions To Drug Promos
• ITC Overstepped In Flipping ALJ Order, Fed. Circ. Says
• Taxation With Representation: Cravath, Simpson Thacher
• GOP Wary Of Attys' Influence On FDA Generics Labeling Rule
• FDA Urged To Add New Black Box Warning On J&J's Levaquin
• LBDS Admits Using Phony Docs In $25M Trade Secrets Suit
• Blackstone-Backed Catalent Aims For $935M IPO
• Medicare Eases Controversial Part D Prior Authorizations
• Mylan Faces $100M Tax Bill Over Drug Agreement With Forest
• 5 Insights From Pfizer Chief Litigation Counsel Michael Parini
• Pfizer Celebrex Suits Should Be Coordinated, Judge Hears
• AbbVie Seals $54B Shire Takeover In Major Inversion Deal
• Powerful Tools For Discovery And Litigation Strategy
• Growing Insistence Among Courts For Ascertainability
• Big Deals, Strong Economy To Keep M&A Cooking
• Corporate Inversions Show No Signs Of Slowing Down
• Kirkland Reps GTCR In $480M Thermo Fisher Carveout
• FedEx Indicted On Charges Of Aiding Illegal Online Pharmacies
• Megamerger Bids Become New Norm As Deal-Making Heats Up
• NJ Mass Torts Judge Bound For Appellate Division
• Deals Rumor Mill: Siemens, Shire, Murphy Oil
• FTC Looks To Join Lamictal Pay-For-Delay Oral Args
• FDA Fine-Tunes Informed Consent Rules
• NJ Judge Won't Disturb $11M Award In J&J Mesh Mass Tort
• PRISM Scatters Attorney-Client Privilege
• FDA Balks At Black Box Warnings On Testosterone Drugs
• $53B Allergan Bid Risks Collapse If No Deal In 2014
• FDA Slaps Concordia Pharmaceuticals Over ADHD Drug Promo
• Employers Directed To Disclose Birth Control Objections
• Dealmakers Q&A: Jenner & Block's Tom Stromberg
• Fighting 'Superbugs' With Next Generation Antibiotics
• OPINION: Let's Financially Reward Law Firm Diversity
• Icahn And Ackman Hug, Publicly End CNBC Feud
• Mylan Scores Block On GSK's Generic Paxil Deal
• FDA Revokes Approval For 7 Acetaminophen Painkillers
• 9th Circ. Affirms Intuitive Win In Investor Class Action
• Deals Rumor Mill: Microsoft, Blackstone, Sanofi
• Google Ad Policies Cloud FDA's Drug Promo Guidance
• Oscar Winner Defends Tweets In Suit Over Endorsement Deal
• Vitamin C Buyers Say AUO Ruling Backs Their Antitrust Case
• Bankrupt Natrol Inks Pact With Cerberus, Quells Trustee Bid
• Medicis Dodges Liability In Acne Drug Hair-Loss Suit
• Teva Says It Doesn't Belong In Pay-For-Delay MDL
• Crucial Predictive Coding Case Law: Progressive V. Delaney
• Calif. Drug Bill Would Frustrate Pharmacy Operations
• Dealmakers Q&A: Ballard Spahr's Craig Circosta
• Bristol-Myers Wants Fed. Circ.'s En Banc Review Of Patent
• 3 Key Facts From The EU's Latest Pay-For-Delay Case
• Iowa Court Offers Limited Boost To Generic-Drug Injury Suits
• Mutual Pharma Inks $9M Deal To Settle Pay-For-Delay Claims
• Bayer Lures Pfizer Atty To Head US Litigation Unit
• Drug Distributor, Pharmacy Settle Contract Suit For $1.65M
• OPINION: Advance Conflict Waivers Send Wrong Message
• FDA Rejects Ban On Controversial Vaginal Mesh Products
• FDA Rips Italian Drug Ingredient Co. For Deleted Test Data
• Actavis Sued Over Generic Morning Sickness Drug
• Ivy Realty Gets $64M For Sandoz's New Jersey HQ
• 8th Circ.'s 'Liberal Admission' Standard Stands Out
• 5th Circ. Frees Pfizer Unit, Others From Generic-Reglan Suit
• Ranbaxy Attacks Hyman Phelps' FDA Exclusivity Petition
• Fed. Circ. Remands Thermometer Patent Suit
• FDA Details Risk-Benefit Stance On 510(k) Device Approvals
• Cephalon Wins Dismissal Of Travelers' $22M Marketing Suit
• NCR Can't Collect Cleanup Costs From Coke, GSK: 6th Circ.
• 5 Tips For Crafting Multistate FCA Settlements
• Wyeth Defends Immunity Bid In Effexor Pay-For-Delay Case
• BigLaw Rips OIG On Medicare Exclusion Time Limits
• Allergan Lobs More Criticism Amid $53B Valeant Buyout Push
• Warner Chilcott To Pay $8M Over Generic Doryx Delay
• Travelers Denies Coverage For Med Co.'s $67M Settlements
• Octane Fitness Gives Medtrica, Steris Second Shot At Fees
• BIO, PhRMA Ask Fed. Circ. To Revisit Double-Patent Ruling
• Fresenius Sued By Cubicin Maker Over Generics Application
• Shire Signals Support For Landmark $53B AbbVie Merger
• Mylan Adds To Inversion Surge With $5.3B Abbott Deal
• Greater Clarity Comes To Nanotech, Courtesy Of The FDA
• Senators Demand Pricing Details On $1,000-Per-Pill Sovaldi
• Whistleblower Again Asks High Court To Mull Leave To Amend
• Novartis Escapes Punitive Damages In Zometa Suit
• US-China Investment Pact Talks May Spur Market Reform
• Wal-Mart Escapes FCA Suit Over Narcotic Prescriptions
• AbbVie Braces For Busy Week Before $51B Shire Bid Deadline
• Iowa High Court Spares Wyeth From Generics Injury Claims
• States May Be Moving To Expand The Federal Sunshine Law
• Covidien Shareholders Sue To Block $42.9B Medtronic Merger
• National Union Denies Coverage For Med Co.'s $100M Suit
• DOJ Scores $2B In FCA Settlements For 1st Half Of 2014
• Deals Rumor Mill: Airbus, WH Group, KKR
• Mass. Gov. Signs Law Reforming Compounding Regs
• Fla. High Court Says No Bright-Line Rule For Sublicensing
• Two Sectors Prove Key To M&A Upswing In 2014
• Pfizer Unit Wants End To Skelaxin Pay-For-Delay 'Odyssey'
• Dr. Reddy's Infringes Cancer Med Patents, Allos Says
• Paul Hastings Adds White Collar Partner From Kaye Scholer
• McGuireWoods Snags IP, Life Sciences Pro For DC Office
• Dealmakers Q&A: Dechert's Daniel O'Donnell
• Legal Forms And IP Rights: Yours, Mine, Ours Or Theirs?
• AbbVie Gets More Humira Patent Claims Invalidated
• FDA Calls Supplement Co.'s Facebook 'Likes' Endorsements
• Biomet Hip Suit Remanded On Distributor Liability Issue
• Thermo Fisher Can't Dodge Suit Over Cartel-Plagued Lab
• Inversion Surge Proves Allure Trumps Risk For Deal Makers
• Backlash Has White House Ready To Drop USPTO Pick
• EU Fines Servier, Others $583M Over Pay-For-Delay Deals
• FDA Clinical Trials Need More Flexibility, Lawmakers Say
• Ireland Posts Big M&A Numbers Amid Pharma, Inversion Deals
• Deals Rumor Mill: Quiron, Televisa, Green Street Advisors
• AbbVie Flouts UK Rules With Comments About Shire Investors
• Medicaid Act May Offer Cause Of Action Against Rate Cuts
• Zogenix Beats Mass. Dismissal Bid In Painkiller Row
• Cadence Sanctioned In Generic Drug Patent Dispute
• Rival Says J&J Unit Monopolizes Glucose Test Strip Market
• Roche, Helsinn Sue Dr. Reddy's Over Generic Aloxi
• Ranbaxy Pays $2.3M To Settle Generic Safety Suit
• Legal Trends And Troubles Involving Medical Marijuana
• Premier Law Firms Making Bank In Valeant-Allergan Battle
• 5 Insights From Home Depot GC Teresa Roseborough
• Hughes Hubbard Dodges Suit From Disgruntled Vioxx Plaintiff
• Guidant Can't Escape J&J's $22B Merger Suit Just Yet
• Stites & Harbison Beefs Up IP, Life Sciences Teams In Tenn.
• AbbVie Raises Shire Offer To $51B, Stoking Buyout Battle
• A Step Toward Alleviating Growing Discovery Problems
• J&J Pays Oregon $4M To Settle Hip Implant Marketing Claims
• Sanofi Sues To Block Unimark's Generic Multaq
• Novel Fights 'Patient' Claim Rehearing In Suprep Suit
• FDA Warns Gilead Of Misleading Google Search Ad
• Patients Sue NJ Hospital Network Over Meningitis Outbreak
• Watchdog Bars Ex-PwC Auditor Over $400M ArthroCare Fraud
• Pfizer Faces 3 Class Actions Over Generic Delay Scheme
• Pershing Square Reveals 6 Picks For Allergan Board
• Novartis Says Gov't Can't Prove Kickbacks Influenced Docs
• Fed. Circ. Upholds $5M Becton IP Award Despite Reversal
• Cuomo Says New Medical Marijuana Bill Delivers Balance
• Deals Rumor Mill: American Apparel, BHP Billiton, Alibaba
• Wilson Sonsini Snags PTAB Judge For IP Practice In DC
• Pfizer Critic Boosts AstraZeneca Ties Amid Talk Of New Bid
• Lawyers And Email: Ethical And Security Considerations
• Deals Rumor Mill: American Apparel, AbbVie, Lululemon
• Affymax To Pay $6.5M To End Class Action Over Anemia Drug
• J&J Gets 12 Cases Transferred Out Of NJ Pelvic Mesh MCL
• Merck Sues To Block Teva's Generic Nasonex
• Sens. Push White House To OK FDA's Lab-Test Guidance
• FTC OKs $500M Valeant-PreCision Deal With Acne Drug Sales
• Cozen O'Connor Nabs Greenberg Traurig, Sedgwick Pros In LA
• Research Firm Asks FDA To Clear Path For Generic Fosamax
• USPTO Tells Fed. Circ. Not To Rethink Clone Patent Ruling
• Sobek Fights For 'Abandoned' Nuprin Mark From Rival
• Dealmakers Q&A: Davis Polk's Michael Davis
• Novartis Beats Ala. Bone Drug Case On Expert Testimony
• 4th Circ. Per-Invoice Rule: Warnings For Gov't Contractors
• More Signs Of Telemedicine Moving Into The Mainstream
• GlaxoSmithKline Gets 219 Avandia Injury Plaintiffs Nixed
• Outcry Over Possible USPTO Pick Is Unfounded, Attys Say
• ArthroCare Execs Can't Duck Verdict In $400M Fraud Scheme
• Nexium Buyers Say Judge Shouldn't Ax Conspiracy Claims
• FDA Pressed To Strengthen Drug Trial Consent Regs
• Roche Unit To Pay Up To $1.7B For US Cancer Drugmaker
• Ex-Novartis Exec Says She Was Fired Over Study Concerns
• Kroger Eyes Bigger Online Biz In $280M Vitacost Pickup
• FTC Asks For More Info On $13.4B Zimmer-Biomet Deal
• Modifying CMS Medicare And Medicaid Incentive Programs
• Alternate Hatch-Waxman Strategies For Branded Pharma
• Novartis Wins Ruling On Duty-To-Warn Scope In Zometa Suit
• Defamation Suit Over Seeking Alpha Blog Post Thrown Out
• FDA Lays Out 4-Year Strategic Priorities Plan
• CooperVision Inks $1.2B Deal To Acquire Sauflon
• 6th Circ. Hobbles Plaintiffs In Generic-Drug Injury Suits
• Fitzpatrick Cella's Managing Partner Surfaces At Mayer Brown
• Fed. Circ. Upholds Ruling Nixing AbbVie Antibody Patents
• Valeant Puts Allergan On Defensive In $53B Buyout Fight
• Deals Rumor Mill: ConvaTec, United Biscuits, ING
• Bausch & Lomb Hits Lupin With IP Suit Over Generic Eye Drug
• GSK Wants 3rd Circ. To Toss RICO Claims In Avandia MDL
• 2014's Top Activist Plays So Far
• FDA Issues 2 Guidances On Drug Compounding
• Forest Labs Slams Ex-Sales Rep's Off-Label Namenda Suit
• Dilworth Paxson, Cryo-Cell Settle Suit Over Lost Contract
• Zurich Ordered To Cover Eisai In Off-Label FCA Suit
• Walgreen, CalPERS Lobby FDA To Drop Biosimilars Naming
• 6 Ways To Update Patent Prosecution Protocols Post-Nautilus